Atai Beckley N.V. (NASDAQ: ATAI)

ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company (NASDAQ: ATAI), is dedicated to transforming the treatment of mental health disorders. The company, established in 2018, focuses on efficiently developing and investing in innovative therapeutics for depression, anxiety, addiction, and other mental health disorders. ATAI's vision is to heal mental health disorders, enabling everyone to live a more fulfilled life.

ATAI's main business activities involve the development of therapeutic candidates across multiple neuropsychiatric indications, including depression, anxiety, opioid use disorders, and cognitive impairment associated with schizophrenia. The company's robust portfolio of drug development programs has been strategically acquired through investments or created de novo through its drug discovery platform.

Revenue for ATAI is generated through its drug development programs, which primarily focus on innovative therapeutics for mental health disorders. The company's product pipeline includes COMP360, a proprietary psilocybin formulation being developed by COMPASS Pathways plc, a company in which ATAI has a strategic investment. COMP360 is being evaluated in a Phase 3 program for treatment-resistant depression, with top-line data expected in the fourth quarter of 2024 and mid-2025. Another key product is BPL-003, a dry powder, intranasal formulation of the benzoate salt form of 5-MeO-DMT, being developed by Beckley Psytech. BPL-003 is being investigated in Phase 2a and 2b studies for treatment-resistant depression and alcohol use disorder.

ATAI's position within the industry is strengthened by its strategic investments in COMPASS Pathways plc and Beckley Psytech, providing access to a robust pipeline of psychedelic compounds and expertise in their development. The company's modular approach to capturing value, including pursuing commercialization of products independently and establishing collaborations or divesting companies, is a key advantage.

The company's customers include COMPASS Pathways plc and Beckley Psytech, both of which are developing psychedelic compounds for mental health disorders. ATAI's products are still in development, and it is expected that they will be commercialized through partnerships with pharmaceutical companies or other organizations.

ATAI's brand names and trade names include COMP360, BPL-003, VLS-01, and IBX-210. These products represent the company's commitment to developing innovative therapeutics for mental health disorders.